Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  ADOCIA    ADOC   FR0011184241

ADOCIA (ADOC)

303
End-of-day quote. End-of-day quote CHI-X EUROPE LIMITED. - 11/30
0.0000 EUR   0.00%
1d ago ELI LILLY : reaches insulin development deal with Adocia
1d ago ADOCIA : Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapi..
10/16 ADOCIA : Announces Third-quarter Financial 2014 Results
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Provides research and development services to the biotechnology field

Adocia SA is a biotechnology company that specializes in the development of medicines from already approved therapeutic agents.

It is also engaged in the research and development of biotheraphy products used in tissue regeneration and for treating chronic diseases.

Its products include pipeline, PDGF-BB, BioChaperone insulins combo based on Glargine, BioChaperone ultra-fast analog insulin, HinsBet, monoclonal antibodies formulations, and DriveIn-Dox.

The company was founded by Gérard Soula, OLivier Soula, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.


Number of employees : 73 persons.
Sales per Businesses
20122013Delta
EUR (in Million)%EUR (in Million)%
Regenerating Medicine4.00100%5.59100% +28.51%
Sales per Regions
20122013Delta
EUR (in Million)%EUR (in Million)%
France4.00100%5.59100% +28.51%
Managers
NameAgeSinceTitle
Gérard Soula PhD, MBA662005Chairman, President & Chief Executive Officer
Valérie Danaguezian-2006CFO, Principal Financial & Accounting Officer
Olivier Soula PhD, MBA452005Director, Deputy General Manager, Director-R&D
Olivier Martinez PhD, MBA44-Director
Laurent Arthaud52-Director
Dominique Takizawa582011Independent Director
Jérôme Féraud39-Director
Ekaterina Smirnyagina, PhD482013Independent Director
Rémi Soula, PhD-2005Director-Business Development
José Correia, PhD--Director-Preclinical & Clinical Department
Shareholders
NameShares%
BPIFrance Investissement SAS 1,129,28018.2%
Gérard Soula PhD, MBA 898,46314.5%
La Société Hospitalière d'Assurances Mutuelles SA 386,1456.21%
ACG Management SAS 364,7545.87%
Rémi Soula, PhD 317,4905.11%
Olivier Soula PhD, MBA 317,4905.11%
IDInvest Partners SA 309,3204.98%
Oreo Finance SAS 191,3433.08%
Groupe des Assurances du Crédit Mutuel SA 125,9442.03%
Amundi Private Equity Funds SA 88,8781.43%
Holdings
NameShares%Valuation
ADOCIA (ADOC) 40,3260.65%1,912,865 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
AGIOS PHARMACEUTI..
RECEPTOS INC
NPS PHARMACEUTICA..
INTERCEPT PHARMAC..
GENMAB A/S
AVANIR PHARMACEUT..
HUALAN BIOLOGICAL..
BEIJING SL PHARMA..
BLUEBIRD BIO INC
TONGHUA DONGBAO P..
MANNKIND CORPORAT..
DYAX CORP.
CLOVIS ONCOLOGY I..
PTC THERAPEUTICS,..
NEUROCRINE BIOSCI..
ACORDA THERAPEUTI..
CHINA BIOLOGIC PR..
Sector Biotechnology & Medical Research
Company contact information
115 avenue Lacassagne
FR-69003 Lyon
France

Phone : +33 (0)4 72 610 610
Fax : +33 (0)4 72 36 39 67
Internet : http://www.adocia.com
Markets and indexes
- PEA / SRD eligible : YES / NO
- Euronext Paris
- Compartiment C
- CAC All Shares / CAC Small, CAC Mid Small, CAC All-Tradable, CAC PME, EnterNext© PEA-PME 150
Stock Exchange Codes
- ISIN Code :  FR0011184241
- Bloomberg Code :  ADOC:FP
- Reuters Code :  ADOC.PA
- Datastream Code :  
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF